Nov 1, 2022, 10:28 AM by

Nov 1, 2022, 10:27 AM by

Nov 1, 2022, 10:26 AM by

Nov 1, 2022, 10:06 AM by

Nov 1, 2022, 10:06 AM by

Nov 1, 2022, 10:05 AM by

Nov 1, 2022, 10:05 AM by

Nov 1, 2022, 10:04 AM by

Nov 1, 2022, 01:00 AM by User Not Found

Bio-IT World | It’s been a big month for sequencing news. Last week, Oxford Nanopore announced the PromethION 2 (“P2”) Solo sequencer and a new collaboration with 10X Genomics to enable a streamlined workflow for sequencing full-length transcripts in single reads.

Oct 31, 2022, 17:33 PM by

Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities

Oct 31, 2022, 17:33 PM by

Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.

Oct 31, 2022, 17:32 PM by

Oct 31, 2022, 17:31 PM by

Oct 28, 2022, 09:37 AM by

Birmingham Biotech LTD, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces that NoriZite™ Nasal Spray, an easy-to-use nasal device designed to block and trap inhaled virus particles, is now available to buy in the UK.

Oct 28, 2022, 09:36 AM by

Samsung Biologics reports third quarter 2022 financial results

Oct 28, 2022, 09:34 AM by

Oct 28, 2022, 09:33 AM by

Oct 27, 2022, 10:12 AM by

Oct 27, 2022, 10:11 AM by

Oct 27, 2022, 10:09 AM by

Contact information Eric Blair, Chief Commercial Officer Eric.Blair@AndelynBio.com For media enquiries, please contact Imogen Quail, PR Manager, imogen.quail@ramarketingpr.com, ramarketingpr.com About Andelyn Biosciences, Inc. Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and drug product manufacturing services. Having 20+ years of experience in viral vector manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders that have enabled 75+ worldwide clinical trials. With the experience gained from over 400 cGMP clinical batches and 2000+ research-grade productions, Andelyn provides its clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply chain vertical integration. Andelyn began operations in its state-of-the-art 200,000 sq. ft. commercial manufacturing facility in September 2022, expanding capacity across 14+ production suites for customization of new programs and tech transferred programs. Andelyn is one of a few select CDMOs that offer clinical through commercial-scale capabilities that will help fulfil Andelyn’s mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Andelyn is owned and supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of Danaher Corporation.